Octreotide therapy in carcinoid disease

Anti-Cancer Drugs

Volumn 7, Issue SUPPL. 1, 1996, Pages 17-22

  Bax, Nigel D S ^a   Woods, H Frank ^a   Batchelor, Aidan ^a   Jennings, Michael ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Carcinoid disease; Octreotide

Indexed keywords

5 HYDROXYINDOLEACETIC ACID; CODEINE; CYPROHEPTADINE; FLUOROURACIL; OCTREOTIDE; SOMATOSTATIN DERIVATIVE;

BREATHING; CANCER SIZE; CARCINOID SYNDROME; CARDIOVASCULAR SYSTEM; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; FLUSHING; HUMAN; HYPERGLYCEMIA; INJECTION PAIN; PRIORITY JOURNAL; REVIEW; STEATORRHEA; SUBCUTANEOUS DRUG ADMINISTRATION; SURVIVAL; SYMPTOM;

ANTINEOPLASTIC AGENTS, HORMONAL; CARCINOID TUMOR; CLINICAL TRIALS; DIARRHEA; FLUSHING; HUMANS; OCTREOTIDE; SOMATOSTATIN;

EID: 0030045305     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199601001-00004     Document Type: Review

References (35)

1. Thorson A. Studies on carcinoid disease. Acta Med Scand 1958; 334 (suppl 7).
2. Buchanan KD, Johnston CF, O'Hare MMT, et al. Neuroendocrine tumours: a European view. Am J Med 1986; 81 (suppl 6B): 14-22.
3. Bax NDS, Woods HF, Batchelor A, Jennings M. The clinical manifestations of carcinoid disease. World J Surg 1996; in press.
4. Moertel CG. Karnofsky Memorial Lecture: An odyssey in the land of small tumours. J Clin Oncol 1987; 5: 1502-1522.
5. Wangberg B, Geterud K, Nilsson O, et al. Embolisation therapy in the midgut carcinoid syndrome: just tumour ischaemia? Acta Oncol 1993; 32: 251-256.
6. Sjoerdsma A. The carcinoid syndrome. In: Beeson PB, McDermott W, eds. Cecil-Loeb textbook of medicine. Philadelphia: WB Saunders, 1971: 1837-1840.
7. Frolich JC, Bloomgarden ZT, Oates JA, McGuigan JE, Rabinowitz D. The carcinoid flush: provocation by pentagastrin and inhibition by somatostatin. N Engl J Med 1978; 299: 1055-1057.
8. Bloom SR, Mortimer CH, Thorner MO, et al. Inhibition of gastrin and gastric acid secretion by growth-hormone release-inhibiting hormone. Lancet 1974; ii: 1106-1109.
9. Barros D'Sa AAB, Bloom SR, Baron JH. Direct inhibition of gastric acid growth-hormone release-inhibiting hormone in dogs. Lancet 1975; 1: 886-887.
10. Long RG, Peters JR, Bloom SR, et al. Somatostatin, gastrointestinal peptides, and the carcinoid syndrome. Gut 1981; 22: 549-553.
11. Davis GR, Camp RC, Raskin P, Krejs GJ. Effect of somatostatin infusion on jejunal water and electrolyte transport in a patient with secretory diarrhea due to malignant carcinoid syndrome. Gastroenterology 1980; 78: 346-349.
12. Dharmsathaphorn K, Sherwin RS, Cataland S, Jaffe B, Dobbins J. Somatostatin inhibits diarrhea in the carcinoid syndrome. Ann Intern Med 1980; 92: 68-69.
13. Bauer W, Briner U, Doepfner W, et al. SMS 201-995: a very potent and selective octapeptide analogue of somatostatin with prolonged action. Life Sci 1982; 31: 1133-1140.
14. Kutz K, Nuesch E, Rosenthaler J. Pharmacokinetics of SMS 201-995 in healthy subjects. Scand J Gastroenterol 1986; 21 (suppl 119): 65-72.
15. Brabant G, Muller MJ, Rotsch M, et al. Treatment of carcinoid syndrome and VIPoma with a long-acting somatostatin analogue (SMS 201-995). Scand J Gastroenterol 1986; 21 (suppl 119): 177-180.
16. Oberg K, Norheim I, Lundqvist G, Wide L. Treatment of the carcinoid syndrome with SMS 201-995, a somatostatin analogue. Scand J Gastroenterol 1986; 21 (suppl 119): 191-192.
17. Buchanan KD, Shaw C, O'Hare MMT, Dalzell G. Evaluation of SMS 201-995 in gastrointestinal APUDomas. Scand J Gastroenterol 1986; 21 (suppl 119): 199-205.
18. Stockmann F, Richter G, Lembcke R, et al. Long-term treatment of patients with endocrine gastrointestinal tumours with the somatostatin analogue SMS 201-995. Scand J Gastroenterol 1986; 21 (suppl 119): 230-237.
19. Tsai ST, Lewis E, Vinik A. The use of a somatostatin analogue (SMS 201-995) in the management of the flushing syndrome. Scand J Gastroenterol 1986; 21 (suppl 119): 267-274.
20. Kvols L, Moertel CG, O'Connell MJ, Schutt AJ, Rubin J, Hahn RG. Treatment of the malignant carcinoid syndrome: evaluation of a long-acting somatostatin analogue. N Engl J Med 1986; 315: 663-666.
21. Kvols LK, Moertel CG, Schutt AJ, Rubin J. Treatment of the malignant carcinoid syndrome with a long acting somatostatin analogue (SMS 201-995): preliminary evidence that more is not better (abstract). Proc Am Soc Clin Oncol 1987; 6: 95.
22. Vinik A, Moattari AR. Use of somatostatin analog in management of carcinoid syndrome. Dig Dis Sci 1989; 34 (3 suppl): 14S-27S.
23. Oberg K, Norheim I, Theodorsson E. Treatment of malignant midgut carcinoid tumours with a long-acting somatostatin analogue octreotide. Acta Oncol 1991; 30: 503-507.
24. Janson ET and Oberg K. Long-term management of the carcinoid syndrome: treatment with octreotide alone and in combination with alpha-interferon. Acta Oncol 1993; 32: 225-229.
25. Anthony L, Johnson D, Hande K, et al. Somatostatin analogue phase I trials in neuroendocrine neoplasms. Acta Oncol 1993; 32: 217-223.
26. Moertel CG, Hanley JA. Combination chemotherapy trials in metastatic carcinoid tumor and the malignant carcinoid syndrome. Cancer Clin Trials 1979; 2: 327-334.
27. De Vries EGE, Kema IP, Slooff MJH, et al. Recent developments in diagnosis and treatment of metastatic carcinoid tumours. Scand J Gastroenterol 1993; 28 (suppl 200): 87-93.
28. Arnold R, Benning R, Neuhaus C, Rolwage M, Trautmann ME, and the German Sandostatin group. Gastroenteropancreatic endocrine tumors: effect of Sandostatin on tumor growth. Metabolism 1992; 41: 116-118.
29. Eriksson B, Bergstrom M, Lilja A, Ahlstrom H, Langstrom B, Oberg K. Positron emission tomography (PET) in neuroendocrine gastrointestinal tumors. Acta Oncol 1993; 32: 189-196.
30. Veall GRQ, Peacock JE, Bax NDS, Reilly CS. Review of the anaesthetic management of 21 patients undergoing laparotomy for carcinoid syndrome. Br J Anaesth 1994; 72: 335-341.
31. Marsh HM, Martin JK, Kvols LK, et al. Carcinoid crisis during anaesthesia: successful treatment with a somatostatin analogue. Anaesthesiology 1987; 66: 88-91.
32. Watson JT, Badner NH, Ali MJ. The prophylactic use of octreotide in a patient with ovarian carcinoid and valvular heart disease. Can J Anaesth 1990; 37: 798-800.
33. Hughes EW, Hodkinson BP. Carcinoid syndrome: the combined use of ketanserin and octreotide in the management of an acute crisis during anaesthesia. Anaesth Intensive Care 1989; 17: 367-370.
34. Janson EM, Ahlstrom H, Andersson T, Oberg KE. Octreotide and interferon alfa: a new combination for the treatment of malignant carcinoid tumors. Eur J Cancer 1992; 28A: 1647-1650.
35. Lamberts SWJ, Krenning EP, Klijn JGM, Reubi J. The clinical use of somatostatin analogues in the treatment of cancer. Clin Endocrinol Metab 1990; 4: 29-49.